Economic TimesIN
US stocks: Summit shares drop after US FDA declines to approve lung cancer drug
Summit Therapeutics faced a notable decline in share value following the FDA's ruling on ivonescimab, which revealed insufficient overall survival benefits during late-stage trials. Despite Summit's emphasis on…